1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Mirabegron |
| brand | String | Myrbetriq |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Beta-3_agonists|β3 adrenergic agonist]] • [[:Category:Overactive_bladder_medications|Overactive bladder medication]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' |
| starting_dose | String | 25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed |
| preparations | String | 25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) |
| fda_max | String | 50 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Symptom improvement within weeks |
| duration | String | 24 hours |
| halflife | String | ~50 hours'"`UNIQ--ref-00000C4E-QINU`"' |
| bioavailability | String | 25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' |
| pregnancy | String | Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
